drugset / Trial / NCT06497517

A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants

NCT06497517

Phase 1 Completed 14 enrolled Bellus Health Inc. - a GSK company
RandomizedCrossoverOpen-labelTreatment

Summary

This study is a single center, single dose, open-label, randomly assigned 2-way crossover study. The study will investigate the food effect on the pharmacokinetics of Camlipixant (GSK5464714) in healthy male and female participants. Eligible participants will be randomized to pre-defined sequences. There will be a washout of minimum 7 days between each dose of treatment period.

Timeline

Start
2024-07-09
Primary completion
2024-08-22
Completion
2024-08-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Camlipixant Small molecule

Indications

No indication recorded.